Research suggests rosuvastatin may benefit certain heart failure patient

From ACC Newsletter

HeartWire (11/3, Stiles) reported, "In a post hoc analysis of the first major trial to have found no statin protective effect overall in patients with chronic heart failure, the efficacy of rosuvastatin...was inversely related to levels of amino-terminal pro-brain natriuretic peptide (NT-proBNP), such that the drug apparently did cut the risk of cardiovascular events in those with less severe disease as gauged by the biomarker." Researchers from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) said that "patients with lower plasma concentrations of NT-proBNP had a lower event rate, but seemed to obtain greater benefit from rosuvastatin." The research was published in the Journal of the American College of Cardiology
Sent from my Verizon Wireless BlackBerry